

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER

This announcement is made by Alphamab Oncology (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

COMPLETION OF PLACING OF EXISTING SHARES BY SHAREHOLDER

Reference is made to the announcement (the “**Announcement**”) of the Company dated June 12, 2020 in relation to, among other things, the Placing. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board has been informed by the Vendor that completion of the Placing took place on June 16, 2020. An aggregate of 14,500,000 Shares, representing approximately 1.55% of the issued share capital of the Company as at the date of this announcement, were successfully placed by the Sole Placing Agent at a price of HK\$16.50 per Share.

The respective shareholdings of the Vendor and other shareholders of the Company immediately upon completion of the Placing are set out below:

	Shareholding immediately upon completion of the Placing	
	Number of Shares held	Approximate % of Shares in issue
The Vendor	314,000,000 ⁽¹⁾	33.6%
Sky Diamond Co., Ltd.	85,750,000	9.2%
Pearlmed Ltd.	85,750,000	9.2%
Other shareholders of the Company	447,965,370	48.0%
Total	933,465,370	100%

Note:

- (1) The entire share capital of the Vendor is wholly owned by South Dakota Trust Company LLC as the trustee of the family trust of Dr. XU Ting, of which Dr. XU Ting acts as the settlor and protector for the benefits of his family members.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, June 16, 2020

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.